


PRODUCT INFORMATION



Prucalopride

Item No. 24192

CAS Registry No.: 179474-81-8
Formal Name: 4-amino-5-chloro-2,3-dihydro-N-[1-(3-methoxypropyl)-4-piperidiny]-7-benzofurancarboxamide
MF: C₁₈H₂₆ClN₃O₃
FW: 367.9
Purity: ≥98%
UV/Vis.: λ_{max}: 225, 276, 300 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Prucalopride is supplied as a crystalline solid. A stock solution may be made by dissolving the prucalopride in the solvent of choice, which should be purged with an inert gas. Prucalopride is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of prucalopride in ethanol and DMSO is approximately 10 mg/ml and approximately 20 mg/ml in DMF.

Prucalopride is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, prucalopride should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Prucalopride has a solubility of approximately 0.1 mg/ml in a 1:9 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Prucalopride is a potent and selective agonist of the serotonin (5-HT) receptor subtype 5-HT₄ (K_is = 2.5 and 8 nM for human 5-HT_{4A} and 5-HT_{4B}, respectively).¹ Prucalopride is greater than 250-fold selective for 5-HT₄ over a panel of 53 overexpressed receptors, including 5-HT subtypes, but does not bind to human dopamine D₄ and sigma-1 (σ₁) receptors and mouse 5-HT₃ receptors (K_is = 2.3, 3.7, and 3.8 μM, respectively). It induces contractions in guinea pig colon with an EC₅₀ value of 33 nM, an effect that is blocked by the 5-HT₄ antagonist GR113808 but not the 5-HT_{2A} and 5-HT₃ antagonists ketanserin (Item No. 22058) and granisetron (Item No. 21239), respectively.² It also facilitates non-cholinergic contractions induced by electrical stimulation. In fasted dogs, oral administration of prucalopride increases colonic motility by inhibiting distal colon contractions (ED₅₀ = 0.04 mg/kg), an effect that is blocked by pretreatment with the 5-HT₄ antagonist GR125487. Prucalopride (5-10 mg/kg, s.c.) increases acetylcholine and histamine levels in the rat prefrontal cortex by 2.4-fold and 3-fold, respectively, and increases the power of hippocampal theta oscillations.³ Formulations containing prucalopride have been used in the treatment of chronic idiopathic constipation.

References

1. Briejer, M.R., Bosmans, J.P., Van Daele, P., et al. *Eur. J. Pharmacol.* **423(1)**, 71-83 (2001).
2. Briejer, M.R., Prins, N.H., and Schuurkes, J.A. *Neurogastroenterol. Motil.* **13(5)**, 465-472 (2001).
3. Johnson, D.E., Drummond, E., Grimwood, S., et al. *J. Pharmacol. Exp. Ther.* **341(3)**, 681-691 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/19/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM